We may request for your doctor's prescription
This is a great Pharmarcy in my area they are the best I have ever seen,feel free to patronize them there Costorma service is best of all time.abiodun nofiuOctober 11, 2021
Doris AtandaMarch 17, 2021
My experience with them was a very good one, the pharmacist on duty took her time to attend to me, answered all my questions and ensured I was satisfied before leaving the premises........ I always love patronizing u guys.Perpetua OyekezieMarch 16, 2021
A perfect place for all your pharmaceutical needs.Kennedy AsonyeMarch 16, 2021
Omobolaji AtandaMarch 15, 2021
abiola odewoleMarch 15, 2021
Ola AdeMarch 15, 2021
lanreatMarch 15, 2021
Olaseni OlanrewajuFebruary 1, 2021
Alawode TosinMay 4, 2020
I love Hugies pharmacy because of their professional approach to customers and standard practice. You get the best hands and quality drugs at Hugies pharmacy Igbogbo.Advert BoardMay 4, 2020
Great people Great products Great qualitySeun Aina-ScottApril 22, 2020
Protein Shakes and Multivitamin Drinks are sold in this Pharmacy. Injections, Antihypertensives, Antidiabetics etc. Interestingly you can check your weight, Blood pressure and some other tests for FREE.Tope SomuwaMarch 17, 2020

Ivermectin confers benefits in the treatment of COVID-19 – Research

Ivermectin confers benefits in the treatment of COVID-19 – Research

Ivermectin confers benefits in the treatment of COVID-19, with a recent study showing that its use helps reduce the risk of death especially in patients with severe pulmonary involvement.

The study included 280 patients (mean age, 59.6 years; 45.4 percent female), 173 of whom received ivermectin and 107 did not. Most patients in both groups were also given hydroxychloroquine, azithromycin, or both.

Ivermectin dosing guidelines were provided, but treatment decisions were left to the treating physician. Most patients received a single dose, while 13 patients received a second dose for ongoing signs or symptoms on day 7 of treatment.

Univariate logistic regression analysis revealed a significant advantage with ivermectin (mortality rate, 15.0 percent vs 25.2 percent; odds ratio [OR] for death, 0.52, 95 percent CI, 0.29–0.96; p=0.03), which was more pronounced in the subgroup of patients with severe pulmonary involvement (mortality rate, 38.8 percent vs 80.7 percent; OR for death, 0.15, 95 percent CI, 0.05–0.47; p=0.001).

The favourable effect of ivermectin on mortality remained despite adjustments for confounders and mortality risks (OR, 0.27, 95 percent CI, 0.09–0.80; p=0.03).

There were no significant differences observed in extubation rates (36.1 percent vs 15.4 percent; OR, 3.11, 95 percent CI, 0.88–11.00; p=0.07) or length of hospital stay.

Results were consistent in a propensity score analysis involving 98 matched pairs. Ivermectin lowered mortality (13.3 percent vs 24.5 percent; OR, 0.47, 95 percent CI, 0.22–0.99; p<0.05), with an 11.2-percent absolute risk reduction and a number needed to treat of 8.9.

Chest 2020;doi:10.1016/j.chest.2020.10.009

First published 21 Nov 2020

Subscribe For Updates

Invalid email address
We promise not to spam you. 

Leave a Reply

Your email address will not be published. Required fields are marked *